[go: up one dir, main page]

EA200001162A1 - Новые лекарственные комбинации ингибиторов повторного поглощения норадреналина (иппна), предпочтительно ребоксетина и пиндолола - Google Patents

Новые лекарственные комбинации ингибиторов повторного поглощения норадреналина (иппна), предпочтительно ребоксетина и пиндолола

Info

Publication number
EA200001162A1
EA200001162A1 EA200001162A EA200001162A EA200001162A1 EA 200001162 A1 EA200001162 A1 EA 200001162A1 EA 200001162 A EA200001162 A EA 200001162A EA 200001162 A EA200001162 A EA 200001162A EA 200001162 A1 EA200001162 A1 EA 200001162A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitors
pindolol
ippne
noradrenalin
drug combination
Prior art date
Application number
EA200001162A
Other languages
English (en)
Other versions
EA003469B1 (ru
Inventor
Дункан Пол Тэйлор
Original Assignee
Фармация Энд Апджон Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармация Энд Апджон Компани filed Critical Фармация Энд Апджон Компани
Publication of EA200001162A1 publication Critical patent/EA200001162A1/ru
Publication of EA003469B1 publication Critical patent/EA003469B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

В данной заявке на патент описан новый объединенный способ лечения на основе селективных ингибиторов повторного поглощения норадреналина (ИППНА) и, особенно, ребоксетина, и пиндолола для обеспечения быстрого ослабления заболеваний у пациентов, страдающих депрессией, общей тревогой, расстройством гиперфунции дефицита внимания (РГДВ) и расстройствами, связанными с тревогой, такими как навязчивые компульсивные расстройства (НКР), панические расстройства (ПР), боязнь общества (социофобия) (БО) и подобные.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200001162A 1998-05-08 1999-04-14 Новые лекарственные комбинации ингибиторов повторного поглощения норадреналина (иппна), предпочтительно ребоксетина и пиндолола EA003469B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8486098P 1998-05-08 1998-05-08
PCT/US1999/006523 WO1999058130A1 (en) 1998-05-08 1999-04-14 New drug combinations of a n.a.r.i., preferably reboxetine, and pindolol

Publications (2)

Publication Number Publication Date
EA200001162A1 true EA200001162A1 (ru) 2001-04-23
EA003469B1 EA003469B1 (ru) 2003-06-26

Family

ID=22187677

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200001162A EA003469B1 (ru) 1998-05-08 1999-04-14 Новые лекарственные комбинации ингибиторов повторного поглощения норадреналина (иппна), предпочтительно ребоксетина и пиндолола

Country Status (22)

Country Link
EP (1) EP1075264B1 (ru)
JP (1) JP2002514601A (ru)
KR (1) KR20010052319A (ru)
CN (1) CN1300217A (ru)
AT (1) ATE283694T1 (ru)
AU (1) AU764579B2 (ru)
BR (1) BR9909559A (ru)
CA (1) CA2326105A1 (ru)
DE (1) DE69922367T2 (ru)
EA (1) EA003469B1 (ru)
ES (1) ES2232128T3 (ru)
HU (1) HUP0101341A3 (ru)
IL (1) IL139211A0 (ru)
NO (1) NO20005621D0 (ru)
NZ (1) NZ508035A (ru)
PL (1) PL345351A1 (ru)
PT (1) PT1075264E (ru)
SI (1) SI1075264T1 (ru)
SK (1) SK14502000A3 (ru)
TR (1) TR200003262T2 (ru)
WO (1) WO1999058130A1 (ru)
ZA (1) ZA200005301B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1632234B1 (en) * 1999-07-01 2007-06-13 Pharmacia & Upjohn Company LLC (S,S)-reboxetine for treating chronic fatigue syndrome
PL196996B1 (pl) 1999-07-01 2008-02-29 Upjohn Co Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
EP1551393A4 (en) 2002-07-30 2010-06-16 Peter Migaly COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
NZ540054A (en) 2002-12-27 2007-09-28 Otsuka Pharma Co Ltd Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
CA2759180A1 (en) * 2009-05-13 2010-11-18 Sunovion Pharmaceuticals Inc. Compositions comprising transnorsertraline and serotonin receptor 1a agonists/antagonists and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
WO1997006792A1 (en) * 1995-08-16 1997-02-27 Eli Lilly And Company Potentiation of serotonin response

Also Published As

Publication number Publication date
AU764579B2 (en) 2003-08-21
AU3546099A (en) 1999-11-29
TR200003262T2 (tr) 2001-03-21
SI1075264T1 (en) 2005-06-30
DE69922367D1 (de) 2005-01-05
EA003469B1 (ru) 2003-06-26
ES2232128T3 (es) 2005-05-16
NO20005621L (no) 2000-11-07
HUP0101341A2 (hu) 2001-08-28
HUP0101341A3 (en) 2006-07-28
NO20005621D0 (no) 2000-11-07
ATE283694T1 (de) 2004-12-15
IL139211A0 (en) 2001-11-25
BR9909559A (pt) 2000-12-19
PL345351A1 (en) 2001-12-17
EP1075264A1 (en) 2001-02-14
JP2002514601A (ja) 2002-05-21
NZ508035A (en) 2004-02-27
SK14502000A3 (sk) 2001-05-10
CN1300217A (zh) 2001-06-20
CA2326105A1 (en) 1999-11-18
WO1999058130A1 (en) 1999-11-18
KR20010052319A (ko) 2001-06-25
PT1075264E (pt) 2005-01-31
ZA200005301B (en) 2001-10-01
EP1075264B1 (en) 2004-12-01
DE69922367T2 (de) 2005-12-22

Similar Documents

Publication Publication Date Title
NO20100333L (no) Behandling av nevrotiske forstyrrelser
BR9714820A (pt) Ligantes não-esteróides para o receptor de estrogênio
MEP6508A (xx) Fenil-piperazin derivati kao inhibitori resorbucije serotonina
TR200401291T4 (tr) Depresyon, obsesif kompülsif bozukluk ve psikozda kullanılmak üzre bir serotonin reuptake inhibitörü ve bir atipik antipsikotik kombinasyonu
DE60026146D1 (de) Verwendung von dapoxetin, a selektiver serotonin-aufnahme inhibitor mit schnellem wirkungseintritt, zur behandlung von sexueller dysfunction
EA200001162A1 (ru) Новые лекарственные комбинации ингибиторов повторного поглощения норадреналина (иппна), предпочтительно ребоксетина и пиндолола
DE69825286D1 (de) Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen
EA200501528A1 (ru) Применение кластерина для лечения и/или профилактики периферических неврологических заболеваний
EA199800152A1 (ru) Лечение синдрома дефицита внимания/гиперактивности
EA200501280A1 (ru) Применение эсциталопрама для лечения приступов паники
ATE334989T1 (de) Antidepressive azaheterocyclylmethyl-derivate von 2,3-dihydro-1,4-dioxino 2,3-föchinoxalin
BRPI0411175A (pt) combinação do modafinil analéptico e um antidepressivo para o tratamento da depressão
BRPI0411174A (pt) combinação do modafinil analéptico e um antidepressivo para o tratamento da depressão
BR0115301A (pt) Uso de um inibidor seletivo da recaptação de norepinefrina
EA200500774A1 (ru) Новая синергетическая комбинация, включающая рофлумиласт и формотерол
ATE239458T1 (de) Verwendung von selegilin zur behandlung von epileptischen erkrankungen
ATE341323T1 (de) Verwendung von darifenacin zur behandlung des harndrangs
CL2009001914A1 (es) Uso de una combinacion de (s)-n-[2-(1,6,7,8-tetrahidro-2h-indeno[5,4-b]furan-8-il)etil]propionamida y una o mas drogas seleccionadas de donepezilo, nivalina, rivastigmina, tacrina y memantine para prevenir o tratar la demencia (divisional de la solicitud 748-06).
BR0206918A (pt) Uso de iloperidona
PT1282414E (pt) Compostos derivados de felbamato para o tratamento da dor neuropatica
CY1115241T1 (el) Χρηση φθοριωμενων τριαζολων για τη θεραπευτικη αντιμετωπιση συναισθηματικων διαταραχων ή διαταραχων της προσοχης
DE50310779D1 (de) Alkoxy-substituierte indanone und deren herstellung
RU2002122996A (ru) ХИРУРГИЧЕСКИЙ КЛЕЙ "Биоклей-ЛАБ"
DE50211837D1 (de) Xenogene oligo- oder/und polyribonukleotide als mittel zur behandlung von malignen tumoren
DK1332229T3 (da) Fremgangsmåde til screening af midler til at behandle overvægt

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU